ROLE OF POLIDOCANOL IN PERCUTANEOUS SCLEROTHERAPY IN TREATMENT OF ANEURYSMAL BONE CYST – A SINGLE-CENTER STUDY

Abstract

Objectives: To study the clinical and radiological outcomes in patients treated with 3% polidocanol as a sclerosing agent in percutaneous sclerotherapy for aneurysmal bone cyst (ABC). Methods: This is a single-centered retrospective study conducted in the Department of Orthopaedics at Kurnool Medical College with 23 patients from 2018 to 2021 over 3 years, where 3% polidocanol was used as a sclerosing agent in percutaneous sclerotherapy as a treatment option for ABC. Postoperatively, patients are evaluated based on clinical and radiological examinations. Results: Clinically, patients were compared to their own Visual Analog Score (VAS) at the time of healing to the VAS score during their first visit. The mean VAS during the first visit was 7.6. At the time of healing, there were only two patients who scored a score of 1 on the VAS. Radiologically, plain radiographs were observed for ossification. 20 (86.9%) patients achieved complete ossification, 2 (8.69%) patients could achieve partial ossification. Conclusion: With this study, we would like to present that percutaneous sclerotherapy with 3% polidocanol is effective both clinically and radiologically in the treatment of ABCs. Our institution has adopted sclerotherapy as part of salvage therapy and as the first line of treatment in treating ABC tumors.